Prof. Nicolas Girard joined us at ASCO 2024 to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress. 

 

Prof. Girard reviewed data from the following studies:

  • LBA8505 - Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced NSCLC: Primary results, including overall survival, from the global, phase 3, randomised controlled PALOMA-3 trial
  • LBA8612 - Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced NSCLC: Results from the phase 2 PALOMA-2 study
  • LBA8503 - Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ NSCLC: 5-year progression-free survival and safety from the CROWN study
  • LBA8509 - KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic NSCLC harbouring a KRASG12C mutation
  • LBA8593 - Safety and anti-tumour activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase 1/2 study
  • Abstract 8514 - Phase 1a/1b trial of zongertinib (BI 1810631), a HER2-specific TKI, in patients with HER2 aberration-positive solid tumours: Updated Phase 1a data from Beamion LUNG-1, including progression-free survival data

 

Watch the short video update and download the accompanying slides to see the key data from these trials.

 

Clinical Takeaways

EGFR:

  • PALOMA-2: provides evidence for the efficacy and safety of subcutaneous amivantamab + lazertinib and suggests it could be suitable as a first-line option for patients with EGFR-mutant advanced NSCLC
  • PALOMA-3: subcutaneous amivantamab with lazertinib is noninferior to intravenous amivantamab plus lazertinib and has an improved safety profile and greater convenience

 

ALK:

  • CROWN: after 5 years of treatment, the median PFS of patients with advanced ALK-positive NSCLC treated with lorlatinib has yet to be reached, corresponding with the longest PFS ever reported in advanced NSCLC

 

KRAS:

  • KRYSTAL-12: adagrasib demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR over docetaxel in patients with previously treated KRASG12C-mutated NSCLC

 

HER2:

  • SOHO-01: in patients with heavily pre-treated HER2-mutant NSCLC, treatment with BAY 2927088 resulted in rapid, substantial and durable responses
  • Beamion LUNG-1: zongertinib was well tolerated and demonstrated promising initial efficacy in pre-treated patients with HER2-mutated NSCLC

Lung cancer data from ASCO 2024: Educational objectives

 

  • Understand the clinical trial data and emerging profile of targeted therapies for the treatment of molecularly driven lung cancer

Nicolas Girard is a pneumologist specialising in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. 

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. 

He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Departement at Institut Curie in Paris.

Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.

Prof. Nicolas Girard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research grants/support from Abbvie, Amgen, AstraZeneca, Beigene, Boehringer  Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen,  Leo Pharma, Lilly, Merk Serono, Merck Sharp & Dohme, Novartis, Sanofi and Sivan.

Consultative services for Abbvie,  Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen  Hoffmann-La Roche, Janssen, Leo Pharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer,  Pierre Fabre, Sanofi and Takeda.

Participation on a data safety monitoring board for Hoffmann-La Roche.

Employment of a family member with AstraZeneca.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED